ERENUMAB, A NEW PREVENTIVE TREATMENT FOR MIGRAINE: MECHANISM OF ACTION, SAFETY AND EFFICACY
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5539Keywords:
Erenumab; Migraine Prophylaxis; CGRP; Monoclonal AntibodiesAbstract
Background: Migraine is a common, debilitating and one of the most disabling of the neurovascular disorders. The common treatment has been based on non-specific medications derived from other clinical disciplines such as beta-blockers, antiepileptics and antidepressants, which have variable efficacy and many unwanted side effects and are therefore frequently discontinued. The recent knowledge about the involvement of CGRP and its receptors in migraine pathophysiology has opened new avenues for anti-migraine treatment.
Objectives: The aim of this paper is to comprehensively review the mechanism of action, clinical efficacy, safety profile, and comparative effectiveness of erenumab - the first fully human monoclonal antibody designed specifically for migraine prevention.
Methods: A narrative review of the current medical literature was conducted using the PubMed database. The analysis included data from phase 2, 3 and 4 randomized controlled trials, long-term open-label extensions, and current international neurological guidelines.
Results: Erenumab is a monoclonal antibody that selectively targets the canonical CGRP receptor and functions as a competitive receptor antagonist. Binding of erenumab to the CGRP receptor does not result in vasoconstriction and does not interact with the CYP450 enzyme system. Studies including STRIVE, ARISE and LIBERTY trials have demonstrated the high efficacy of erenumab in the reduction of MMD in both EM and CM patients, including those who have failed multiple prior prophylactic treatments. The HER-MES trial has further confirmed the high tolerability of erenumab and a higher retention rate compared to topiramate. The safety profile is highly favorable, with injection site reactions and constipation being the most frequently reported adverse events. Furthermore, erenumab can safely be given alongside with novel acute treatments, such as gepants and ditans.
Conclusions: Erenumab holds great promise in migraine prophylaxis as it’s offering a targeted, highly effective, and well-tolerated therapeutic option. Future research should focus on its long-term efficacy in a real-world setting. One important aspect will be to explore its safety during pregnancy and in children. An interesting and potentially clinically useful aspect for non-responders will be exploring the possibility of combining it with antibodies against other neuropeptide pathways, such as those involving PACAP.
References
GBD 2019 Diseases and Injuries Collaborators. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396(10258), 1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9
Stovner, L. J., Nichols, E., Steiner, T. J., et al. (2018). Global, regional, and national burden of migraine and tension-type headache, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 17(11), 954–976. https://doi.org/10.1016/S1474-4422(18)30322-3
Burch, R. C., Buse, D. C., & Lipton, R. B. (2019). Migraine: Epidemiology, burden, and comorbidity. Neurologic Clinics, 37(4), 631–649. https://doi.org/10.1016/j.ncl.2019.06.001
Frimpong-Manson, K., Ortiz, Y. T., McMahon, L. R., & Wilkerson, J. L. (2024). Advances in understanding migraine pathophysiology: A bench-to-bedside review of research insights and therapeutics. Frontiers in Molecular Neuroscience, 17, Article 1355281. https://doi.org/10.3389/fnmol.2024.1355281
Fermo, O. P. (2021). Underdiagnosis and undertreatment of migraine in Poland. Neurologia i Neurochirurgia Polska, 55(4), 331–332. https://doi.org/10.5603/PJNNS.a2021.0046
Pescador Ruschel, M. A., & De Jesus, O. (2024). Migraine headache. In StatPearls. StatPearls Publishing.
Charles, A. (2018). The pathophysiology of migraine: Implications for clinical management. The Lancet Neurology, 17(2), 174–182. https://doi.org/10.1016/S1474-4422(17)30435-0
Ashina, M., Hansen, J. M., Do, T. P., Melo-Carrillo, A., Burstein, R., & Moskowitz, M. A. (2019). Migraine and the trigeminovascular system—40 years and counting. The Lancet Neurology, 18(8), 795–804. https://doi.org/10.1016/S1474-4422(19)30185-1
Dodick, D. W. (2018). A phase-by-phase review of migraine pathophysiology. Headache, 58(Suppl. 1), 4–16. https://doi.org/10.1111/head.13300
Ayata, C. (2010). Cortical spreading depression triggers migraine attack: Pro. Headache, 50(4), 725–730. https://doi.org/10.1111/j.1526-4610.2010.01647.x
Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018). CGRP as the target of new migraine therapies: Successful translation from bench to clinic. Nature Reviews Neurology, 14(6), 338–350. https://doi.org/10.1038/s41582-018-0003-1
Russo, A. F., & Kaiser, E. A. (2026). CGRP and migraine: Real-world insights and future therapeutic directions. Annual Review of Medicine, 77(1), 415–432. https://doi.org/10.1146/annurev-med-050224-111631
Tanaka, M., Szabó, Á., Körtési, T., Szok, D., Tajti, J., & Vécsei, L. (2023). From CGRP to PACAP, VIP, and beyond: Unraveling the next chapters in migraine treatment. Cells, 12(22), Article 2649. https://doi.org/10.3390/cells12222649
Pietra, A. D., Kuburas, A., & Russo, A. F. (2025). PACAP versus CGRP in migraine: From mouse models to clinical translation. Cephalalgia, 45(9), Article 03331024251364242. https://doi.org/10.1177/03331024251364242
Sreevani, N., Ramesh, B., Maheshkumar, K., & Thanalakshmi, J. (2025). Comparative analysis of CGRP, VIP and PACAP-38 levels in migraine with and without aura: A case-control study. Annals of Neurosciences. Advance online publication. https://doi.org/10.1177/09727531251340156
Headache Classification Committee of the International Headache Society. (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1–211. https://doi.org/10.1177/0333102417738202
Do, T. P., Remmers, A., Schytz, H. W., Schankin, C., Nelson, S. E., Obermann, M., Hansen, J. M., Sinclair, A. J., Gantenbein, A. R., & Schoonman, G. G. (2019). Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Neurology, 92(3), 134–144. https://doi.org/10.1212/WNL.0000000000006697
Olesen, J. (2018). International Classification of Headache Disorders. The Lancet Neurology, 17(5), 396–397. https://doi.org/10.1016/S1474-4422(18)30085-1
Gama-Reyes, E. G., de Caceres-García, A. N., Castillo-Vaca, M. F., Hernandez-Ramirez, J., Jimenez-Romo, A. E., Fuentes-Mendoza, J. M., Rodríguez-Lizarraga, E., Díaz-Garza, C. A., & Galnares-Olalde, J. A. (2025). Migraine-like headaches: A systematic review of secondary etiologies, clinical features and therapeutic patterns (1977–2024). The Journal of Headache and Pain, 26(1), Article 232. https://doi.org/10.1186/s10194-025-02151-8
Overeem, L. H., Ulrich, M., Fitzek, M. P., Lange, K. S., Hong, J. B., Reuter, U., & Raffaelli, B. (2025). Consistency between headache diagnoses and ICHD-3 criteria across different levels of care. The Journal of Headache and Pain, 26(1), Article 6. https://doi.org/10.1186/s10194-024-01937-6
Ailani, J., Burch, R. C., Robbins, M. S., & Board of Directors of the American Headache Society. (2021). The American Headache Society consensus statement: Update on integrating new migraine treatments into clinical practice. Headache, 61(7), 1021–1039. https://doi.org/10.1111/head.14153
Tzankova, V., Becker, W. J., & Chan, T. L. H. (2023). Diagnosis and acute management of migraine. CMAJ, 195(4), E153–E158. https://doi.org/10.1503/cmaj.211969
Ong, J. J. Y., & De Felice, M. (2018). Migraine treatment: Current acute medications and their potential mechanisms of action. Neurotherapeutics, 15(2), 274–290. https://doi.org/10.1007/s13311-017-0592-1
Marmura, M. J., Silberstein, S. D., & Schwedt, T. J. (2015). The acute treatment of migraine in adults: The American Headache Society evidence assessment of migraine pharmacotherapies. Headache, 55(1), 3–20. https://doi.org/10.1111/head.12499
Derry, S., & Moore, R. A. (2013). Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews, 2013(4), Article CD008040. https://doi.org/10.1002/14651858.CD008040.pub3
Cameron, C., Kelly, S., Hsieh, S. C., Murphy, M., Chen, L., Kotb, A., Peterson, J., Coyle, D., Skidmore, B., Gomes, T., Clifford, T., & Wells, G. (2015). Triptans in the acute treatment of migraine: A systematic review and network meta-analysis. Headache, 55(Suppl. 4), 221–235. https://doi.org/10.1111/head.12601
Johnston, M. M., & Rapoport, A. M. (2010). Triptans for the management of migraine. Drugs, 70(12), 1505–1518. https://doi.org/10.2165/11537990-000000000-00000
Tfelt-Hansen, P., De Vries, P., & Saxena, P. R. (2000). Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs, 60(6), 1259–1287. https://doi.org/10.2165/00003495-200060060-00003
Silberstein, S. D. (2000). Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review) [Retired]: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 55(6), 754–762. https://doi.org/10.1212/WNL.55.6.754
Tfelt-Hansen, P. C., & Koehler, P. J. (2008). History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia, 28(8), 877–886. https://doi.org/10.1111/j.1468-2982.2008.01578.x
Croop, R., Goadsby, P. J., Stock, D. A., Conway, C. M., Forshaw, M., Stock, E. G., Coric, V., & Lipton, R. B. (2019). Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double-blind, placebo-controlled trial. The Lancet, 394(10200), 737–745. https://doi.org/10.1016/S0140-6736(19)31606-X
Dodick, D. W., Lipton, R. B., Ailani, J., et al. (2019). Ubrogepant for the treatment of migraine. The New England Journal of Medicine, 381(23), 2230–2241. https://doi.org/10.1056/NEJMoa1813049
Dodick, D. W., Lipton, R. B., Ailani, J., Lu, K., Finnegan, M., Trugman, J. M., & Szegedi, A. (2019). Ubrogepant for the treatment of migraine. The New England Journal of Medicine, 381(23), 2230–2241. https://doi.org/10.1056/NEJMoa1813049
Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., Ashman, E., Quality Standards Subcommittee of the American Academy of Neurology, & American Headache Society. (2012). Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Neurology, 78(17), 1337–1345. https://doi.org/10.1212/WNL.0b013e3182535d20
Kumar, A., & Kadian, R. (2023). Migraine prophylaxis. In StatPearls. StatPearls Publishing.
Ha, H., & Gonzalez, A. (2019). Migraine headache prophylaxis. American Family Physician, 99(1), 17–24.
Pringsheim, T., Davenport, W., Mackie, G., Worthington, I., Aubé, M., Christie, S. N., Gladstone, J., Becker, W. J., & Canadian Headache Society Prophylactic Guidelines Development Group. (2012). Canadian Headache Society guideline for migraine prophylaxis. Canadian Journal of Neurological Sciences, 39(Suppl. 2), S1–S59.
Burch, R. C., Loder, S., Loder, E., & Smitherman, T. A. (2015). The prevalence and burden of migraine and severe headache in the United States: Updated statistics from government health surveillance studies. Headache, 55(1), 21–34. https://doi.org/10.1111/head.12482
Hepp, Z., Dodick, D. W., Varon, S. F., Chia, J., Matthew, N., Gillard, P., Hansen, R. N., & Devine, E. B. (2017). Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. Cephalalgia, 37(5), 470–485. https://doi.org/10.1177/0333102416678382
Tassorelli, C., Diener, H. C., Dodick, D. W., Silberstein, S. D., Lipton, R. B., Ashina, M., Becker, W. J., Ferrari, M. D., Goadsby, P. J., Pozo-Rosich, P., Wang, S. J., & International Headache Society Clinical Trials Standing Committee. (2018). Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia, 38(5), 815–832. https://doi.org/10.1177/0333102418758283
Herd, C. P., Tomlinson, C. L., Rick, C., Scotton, W. J., Edwards, J., Ives, N., Clarke, C. E., & Sinclair, A. (2018). Botulinum toxins for the prevention of migraine in adults. Cochrane Database of Systematic Reviews, 2018(6), Article CD011616. https://doi.org/10.1002/14651858.CD011616.pub2
Haghdoost, F., & Togha, M. (2022). Migraine management: Non-pharmacological points for patients and health care professionals. Open Medicine, 17(1), 1869–1882. https://doi.org/10.1515/med-2022-0598
Kelman, L. (2007). The triggers or precipitants of the acute migraine attack. Cephalalgia, 27(5), 394–402. https://doi.org/10.1111/j.1468-2982.2007.01303.x
Minen, M. T., Begasse De Dhaem, O., Kroon Van Diest, A., Powers, S., Schwedt, T. J., Lipton, R., & Silbersweig, D. (2016). Migraine and its psychiatric comorbidities. Journal of Neurology, Neurosurgery & Psychiatry, 87(7), 741–749. https://doi.org/10.1136/jnnp-2015-312233
Harris, P., Loveman, E., Clegg, A., Easton, S., & Berry, N. (2015). Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults. British Journal of Pain, 9(4), 213–224. https://doi.org/10.1177/2049463715578291
Puledda, F., & Goadsby, P. J. (2017). An update on non-pharmacological neuromodulation for the acute and preventive treatment of migraine. Headache, 57(4), 685–691. https://doi.org/10.1111/head.13069
D’Onofrio, F., Raimo, S., Spitaleri, D., Casucci, G., & Bussone, G. (2017). Usefulness of nutraceuticals in migraine prophylaxis. Neurological Sciences, 38(Suppl. 1), 117–120. https://doi.org/10.1007/s10072-017-2901-1
Tepper, S. J. (2015). Nutraceutical and other modalities for the treatment of headache. Continuum, 21(4, Headache), 1018–1031. https://doi.org/10.1212/CON.0000000000000211
Airola, G., Allais, G., Castagnoli Gabellari, I., Rolando, S., Mana, O., & Benedetto, C. (2010). Non-pharmacological management of migraine during pregnancy. Neurological Sciences, 31(Suppl. 1), S63–S65. https://doi.org/10.1007/s10072-010-0276-7
Markham, A. (2018). Erenumab: First global approval. Drugs, 78(11), 1157–1161. https://doi.org/10.1007/s40265-018-0944-0
Goadsby, P. J., Reuter, U., Hallström, Y., Broessner, G., Bonner, J. H., Zhang, F., Sapra, S., Picard, H., Mikol, D. D., & Lenz, R. A. (2017). A controlled trial of erenumab for episodic migraine. The New England Journal of Medicine, 377(22), 2123–2132. https://doi.org/10.1056/NEJMoa1705848
Deen, M., Correnti, E., Kamm, K., Kelderman, T., Papetti, L., Rubio-Beltrán, E., Vigneri, S., Edvinsson, L., Maassen Van Den Brink, A., & European Headache Federation School of Advanced Studies. (2017). Blocking CGRP in migraine patients: A review of pros and cons. The Journal of Headache and Pain, 18(1), Article 96. https://doi.org/10.1186/s10194-017-0807-1
Vu, T., Ma, P., Chen, J. S., de Hoon, J., Van Hecken, A., Yan, L., Wu, L. S., Hamilton, L., & Vargas, G. (2017). Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects. Pharmaceutical Research, 34(9), 1784–1795. https://doi.org/10.1007/s11095-017-2183-6
Russell, F. A., King, R., Smillie, S. J., Kodji, X., & Brain, S. D. (2014). Calcitonin gene-related peptide: Physiology and pathophysiology. Physiological Reviews, 94(4), 1099–1142. https://doi.org/10.1152/physrev.00034.2013
Booe, J. M., Walker, C. S., Barwell, J., Kuteyi, G., Simms, J., Jamaluddin, M. A., Warner, M. L., Bill, R. M., Harris, P. W., Brimble, M. A., Poyner, D. R., Hay, D. L., & Pioszak, A. A. (2015). Structural basis for receptor activity-modifying protein-dependent selective peptide recognition by a G protein-coupled receptor. Molecular Cell, 58(6), 1040–1052. https://doi.org/10.1016/j.molcel.2015.04.018
Ashina, M. (2020). Migraine. The New England Journal of Medicine, 383(19), 1866–1876. https://doi.org/10.1056/NEJMra1915327
Messlinger, K., & Russo, A. F. (2019). Current understanding of trigeminal ganglion structure and function in headache. Cephalalgia, 39(13), 1661–1674. https://doi.org/10.1177/0333102418786261
Vidarsson, G., Dekkers, G., & Rispens, T. (2014). IgG subclasses and allotypes: From structure to effector functions. Frontiers in Immunology, 5, Article 520. https://doi.org/10.3389/fimmu.2014.00520
European Medicines Agency. (n.d.). Aimovig (erenumab): Summary of product characteristics. Retrieved March 2026, from https://www.ema.europa.eu/en/documents/product-information/aimovig-epar-product-information_en.pdf
U.S. Food and Drug Administration. (n.d.). Aimovig (erenumab-aooe) injection, for subcutaneous use: Prescribing information. Retrieved March 2026, from https://www.accessdata.fda.gov
Sacco, S., Bendtsen, L., Ashina, M., Reuter, U., Terwindt, G., Mitsikostas, D. D., & Martelletti, P. (2019). European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene-related peptide or its receptor for migraine prevention. The Journal of Headache and Pain, 20(1), Article 6. https://doi.org/10.1186/s10194-018-0955-y
Tso, A. R., & Goadsby, P. J. (2017). Anti-CGRP monoclonal antibodies: The next era of migraine prevention? Current Treatment Options in Neurology, 19(8), Article 27. https://doi.org/10.1007/s11940-017-0463-4
Pellesi, L., Guerzoni, S., & Pini, L. A. (2017). Spotlight on anti-CGRP monoclonal antibodies in migraine: The clinical evidence to date. Clinical Pharmacology in Drug Development, 6(6), 534–547. https://doi.org/10.1002/cpdd.345
Favoni, V., Giani, L., Al-Hassany, L., Asioli, G. M., Butera, C., de Boer, I., Guglielmetti, M., Koniari, C., Mavridis, T., Vaikjärv, M., Verhagen, I., Verzina, A., Zick, B., Martelletti, P., Sacco, S., & European Headache Federation School of Advanced Studies. (2019). CGRP and migraine from a cardiovascular point of view: What do we expect from blocking CGRP? The Journal of Headache and Pain, 20(1), Article 27. https://doi.org/10.1186/s10194-019-0979-y
Tepper, S. J., Sheikh, H. U., Dougherty, C. O., Nahas, S. J., Winner, P. K., Karanam, A. K., Blumenfeld, A. M., Abdrabboh, A., Rasmussen, S., Weiss, J. L., & Ailani, J. (2022). Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations. Headache, 62(4), 420–435. https://doi.org/10.1111/head.14266
Hershey, A. D., Paiva da Silva Lima, G., Pannacciulli, N., Mackowski, M., Koukakis, R., & McVige, J. W. (2024). Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open-label, multiple-dose study. Clinical and Translational Science, 17(3), Article e13755. https://doi.org/10.1111/cts.13755
de Vries Lentsch, S., Verhagen, I. E., van den Hoek, T. C., MaassenVanDenBrink, A., & Terwindt, G. M. (2021). Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study. European Journal of Neurology, 28(12), 4194–4203. https://doi.org/10.1111/ene.15075
Romozzi, M., Palermo, M., Danno, D., Katsuki, M., Tosto, F., Signorelli, F., Vollono, C., Matsumori, Y., Calabresi, P., Ornello, R., & Iannone, L. F. (2026). Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: An individual patient quantitative analysis. The Journal of Headache and Pain, 27(1), Article 56. https://doi.org/10.1186/s10194-026-02283-5
Sun, H., Dodick, D. W., Silberstein, S., Goadsby, P. J., Reuter, U., Ashina, M., Saper, J., Cady, R., Chon, Y., Dietrich, J., & Lenz, R. (2016). Safety and efficacy of AMG 334 for prevention of episodic migraine: A randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology, 15(4), 382–390. https://doi.org/10.1016/S1474-4422(16)00019-3
Ashina, M., Buse, D. C., Ashina, H., Pozo-Rosich, P., Peres, M. F. P., Lee, M. J., Terwindt, G. M., Halker Singh, R., Tassorelli, C., Do, T. P., Mitsikostas, D. D., & Dodick, D. W. (2021). Migraine: Integrated approaches to clinical management and emerging treatments. The Lancet, 397(10283), 1505–1518. https://doi.org/10.1016/S0140-6736(20)32342-4
Chomistek, A. K., Hoffman, V., Urman, R., Gill, K. S., Ezzy, S. M., Zhou, L., Park, A. S., Loop, B., Lopez-Leon, S., McAllister, P., & Wang, F. T. (2022). Inpatient constipation among migraine patients prescribed anti-calcitonin gene-related peptide monoclonal antibodies and standard-of-care antiepileptic drugs: A retrospective cohort study in a United States electronic health record database. Pain and Therapy, 11(4), 1415–1437. https://doi.org/10.1007/s40122-022-00440-7
Holzer, P., & Holzer-Petsche, U. (2022). Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine. Frontiers in Physiology, 12, Article 820006. https://doi.org/10.3389/fphys.2021.820006
Saely, S., Croteau, D., Jawidzik, L., Brinker, A., & Kortepeter, C. (2021). Hypertension: A new safety risk for patients treated with erenumab. Headache, 61(1), 202–208. https://doi.org/10.1111/head.14051
Datta, A., Gupta, S., Maryala, S., Aggarwal, V., Chopra, P., & Jain, S. (2022). Erenumab for episodic migraine. Pain Management, 12(5), 587–594. https://doi.org/10.2217/pmt-2021-0077
Lipton, R. B., Tepper, S. J., Reuter, U., Silberstein, S., Stewart, W. F., Nilsen, J., Leonardi, D. K., Desai, P., Cheng, S., Mikol, D. D., & Lenz, R. (2019). Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. Neurology, 92(19), e2250–e2260. https://doi.org/10.1212/WNL.0000000000007452
Dodick, D. W., Ashina, M., Brandes, J. L., Kudrow, D., Lanteri-Minet, M., Osipova, V., Palmer, K., Picard, H., Mikol, D. D., & Lenz, R. A. (2018). ARISE: A phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia, 38(6), 1026–1037. https://doi.org/10.1177/0333102418759786
Tepper, S., Ashina, M., Reuter, U., Brandes, J. L., Doležil, D., Silberstein, S., Winner, P., Leonardi, D., Mikol, D., & Lenz, R. (2017). Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology, 16(6), 425–434. https://doi.org/10.1016/S1474-4422(17)30083-2
Buse, D. C., Lipton, R. B., Hallström, Y., Reuter, U., Tepper, S. J., Zhang, F., Sapra, S., Picard, H., Mikol, D. D., & Lenz, R. A. (2018). Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia, 38(10), 1622–1631. https://doi.org/10.1177/0333102418789072
Reuter, U., Goadsby, P. J., Lanteri-Minet, M., Wen, S., Hours-Zesiger, P., Ferrari, M. D., & Klatt, J. (2018). Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study. The Lancet, 392(10161), 2280–2287. https://doi.org/10.1016/S0140-6736(18)32534-0
Lanteri-Minet, M., Goadsby, P. J., Reuter, U., Wen, S., Hours-Zesiger, P., Ferrari, M. D., & Klatt, J. (2021). Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: Results from the LIBERTY study. Journal of Neurology, Neurosurgery & Psychiatry, 92(5), 466–472. https://doi.org/10.1136/jnnp-2020-324396
Ashina, M., Goadsby, P. J., Reuter, U., Silberstein, S., Dodick, D. W., Xue, F., Zhang, F., Paiva da Silva Lima, G., Cheng, S., & Mikol, D. D. (2021). Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. European Journal of Neurology, 28(5), 1716–1725. https://doi.org/10.1111/ene.14715
Tepper, S. J., Ashina, M., Reuter, U., Brandes, J. L., Doležil, D., Silberstein, S. D., Winner, P., Zhang, F., Cheng, S., & Mikol, D. D. (2020). Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. Cephalalgia, 40(6), 543–553. https://doi.org/10.1177/0333102420912726
Dirks, N. L., & Meibohm, B. (2010). Population pharmacokinetics of therapeutic monoclonal antibodies. Clinical Pharmacokinetics, 49(10), 633–659. https://doi.org/10.2165/11535960-000000000-00000
Jakate, A., Boinpally, R., Butler, M., Lu, K., McGeeney, D., & Periclou, A. (2020). Evaluation of the pharmacokinetic interaction of ubrogepant coadministered with sumatriptan and of the safety of ubrogepant with triptans. Headache, 60(7), 1340–1350. https://doi.org/10.1111/head.13862
Xu, Y., Gabriel, K., Wang, Y., Zhou, Y., Eisele, O., Vutikullird, A., Mikol, D. D., & Lee, E. (2019). A multi-center, open-label, pharmacokinetic drug interaction study of erenumab and a combined oral contraceptive in healthy females. CNS Drugs, 33(5), 513–522. https://doi.org/10.1007/s40263-019-00626-2
Vig, S. J., Garza, J., & Tao, Y. (2022). The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review. Headache, 62(10), 1256–1263. https://doi.org/10.1111/head.14305
Reuter, U., Ehrlich, M., Gendolla, A., Heinze, A., Klatt, J., Wen, S., Hours-Zesiger, P., Nickisch, J., Sieder, C., Hentschke, C., & Maier-Peuschel, M. (2022). Erenumab versus topiramate for the prevention of migraine: A randomised, double-blind, active-controlled phase 4 trial. Cephalalgia, 42(2), 108–118. https://doi.org/10.1177/03331024211053571
Rizzoli, P. B. (2012). Acute and preventive treatment of migraine. Continuum, 18(4), 764–782. https://doi.org/10.1212/01.CON.0000418641.45522.3b
Wang, X., Chen, Y., Song, J., & You, C. (2021). Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: A systematic review and network meta-analysis. Frontiers in Pharmacology, 12, Article 649143. https://doi.org/10.3389/fphar.2021.649143
Wang, X., Wen, D., He, Q., You, C., & Ma, L. (2022). Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: A network meta-analysis. The Journal of Headache and Pain, 23(1), Article 105. https://doi.org/10.1186/s10194-022-01472-2
Ailani, J., Lipton, R. B., Goadsby, P. J., Guo, H., Miceli, R., Severt, L., Finnegan, M., Trugman, J. M., & ADVANCE Study Group. (2021). Atogepant for the preventive treatment of migraine. The New England Journal of Medicine, 385(8), 695–706. https://doi.org/10.1056/NEJMoa2035908
Jakubowska, B., & Sowa-Kućma, M. (2025). Gepants: Targeting the CGRP pathway for migraine relief. Frontiers in Pharmacology, 16, Article 1708226. https://doi.org/10.3389/fphar.2025.1708226
Clemow, D. B., Johnson, K. W., Hochstetler, H. M., Ossipov, M. H., Hake, A. M., & Blumenfeld, A. M. (2020). Lasmiditan mechanism of action: Review of a selective 5-HT1F agonist. The Journal of Headache and Pain, 21(1), Article 71. https://doi.org/10.1186/s10194-020-01132-3
Goadsby, P. J., Wietecha, L. A., Dennehy, E. B., Kuca, B., Case, M. G., Aurora, S. K., & Gaul, C. (2019). Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain, 142(7), 1894–1904. https://doi.org/10.1093/brain/awz134
Straube, A., Stude, P., Gaul, C., Schuh, K., & Koch, M. (2021). Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: Perspectives of treating physicians in Germany. The Journal of Headache and Pain, 22(1), Article 133. https://doi.org/10.1186/s10194-021-01344-1
Szperka, C. L., VanderPluym, J., Orr, S. L., Oakley, C. B., Qubty, W., Patniyot, I., Lagman-Bartolome, A. M., Morris, C., Gautreaux, J., Victorio, M. C., Hagler, S., Narula, S., Candee, M. S., Cleves-Bayon, C., Rao, R., Fryer, R. H., Bicknese, A. R., Yonker, M., Hershey, A. D., . . . Gelfand, A. A. (2018). Recommendations on the use of anti-CGRP monoclonal antibodies in children and adolescents. Headache, 58(10), 1658–1669. https://doi.org/10.1111/head.13414
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Mikołaj Jońca, Natasza Kurys, Mikhail Kazachok, Szymon Paruszewski , Julia Kupczak, Aleksandra Dybcio , Katarzyna Kupczyk, Dorota Szydłowska , Adam Kubisa, Mateusz Miluski
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
